Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐ho...

por Kiyosue, Arihiro, Seino, Yutaka, Nishijima, Keiji, Bosch‐Traberg, Heidrun, Kaku, Kohei
Publicado 2017

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical tria...

por Kaneko, Shizuka, Nishijima, Keiji, Bosch‐Traberg, Heidrun, Kaku, Kohei, Seino, Yutaka
Publicado 2018

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide...

por Seino, Yutaka, Miyoshi, Hideaki, Bosch Traberg, Heidrun, Divyalasya, T V S, Nishijima, Keiji, Terauchi, Yasuo
Publicado 2022

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐gro...

por Kaku, Kohei, Kiyosue, Arihiro, Ono, Yuri, Shiraiwa, Toshihiko, Kaneko, Shizuka, Nishijima, Keiji, Bosch‐Traberg, Heidrun, Seino, Yutaka
Publicado 2015

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial

por Seino, Yutaka, Kaneko, Shizuka, Fukuda, Shuichi, Osonoi, Takeshi, Shiraiwa, Toshihiko, Nishijima, Keiji, Bosch‐Traberg, Heidrun, Kaku, Kohei
Publicado 2016